- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01322581
A Longitudinal Systems Biological Analysis of Naturally Acquired Malaria Immunity in Mali
29. März 2022 aktualisiert von: National Institute of Allergy and Infectious Diseases (NIAID)
Plasmodium falciparum (Pf) malaria remains a major cause of morbidity and mortality worldwide.
A malaria vaccine would contribute towards efforts to control and eliminate malaria.
Optimism that an effective malaria vaccine can be developed is derived in part from the observation that repeated Pf infections can induce protective immunity; however, the mechanisms underlying acquired malaria immunity remain unclear.
The goal of the current study is to apply systems biological tools to an observational cohort in an area of intense seasonal Pf transmission to gain insight into the mechanisms underlying naturally acquired malaria immunity.
This year-long observational-cohort study of 700 individuals (3 months and 25 years of age) will be conducted in the rural village of Kalifabougou, Mali, where Pf transmission is intense and seasonal.
Asymptomatic Pf infection and malaria episodes will be detected by passive and active surveillance.
Immune parameters of malaria-protected and -susceptible individuals will be assayed from blood samples collected at strategic time points relative to the malaria season.
The primary objective is to identify genome-wide expression profiles induced by Pf infection that are associated with protection from malaria.
Secondary objectives include identifying age-related (surrogate for cumulative Pf exposure) changes in Pf-induced gene-expression and serum cytokine profiles, and examining Pf-specific antibody profiles that are associated with protection from malaria using a protein microarray representing 2000 Pf proteins (40 percent of the Pf proteome).
Exploratory objectives for this study are to compare the magnitude and quality of the Pf-specific CD4 plus T cell response in malaria-protected and -susceptible individuals and determine how this response varies with age and among individuals before, during, and after malaria season, as well as compare various immune parameters in Pf-infected and uninfected individuals at the end of the dry season to investigate host immune factors associated with chronic asymptomatic Pf infection....
Studienübersicht
Status
Abgeschlossen
Bedingungen
Detaillierte Beschreibung
Plasmodium falciparum (Pf) malaria remains a major cause of morbidity and mortality worldwide.
A malaria vaccine would contribute towards efforts to control and eliminate malaria.
Optimism that an effective malaria vaccine can be developed is derived in part from the observation that repeated Pf infections can induce protective immunity; however, the mechanisms underlying acquired malaria immunity remain unclear.
The goal of the current study is to apply systems biological tools to an observational cohort in an area of intense seasonal Pf transmission to gain insight into the mechanisms underlying naturally acquired malaria immunity.
This observational-cohort study of individuals (3 months and 40 years of age) will be conducted in the rural village of Kalifabougou, Mali, where Pf transmission is intense and seasonal.
Asymptomatic Pf infection and malaria episodes will be detected by passive and active surveillance.
Immune parameters of malaria-protected and -susceptible individuals will be assayed from blood samples collected at strategic time points relative to the malaria season.
The primary objective is to identify genome-wide expression profiles induced by Pf infection that are associated with protection from malaria.
Secondary objectives include identifying age-related (surrogate for cumulative Pf exposure) changes in Pf-induced gene-expression and serum cytokine profiles, and examining Pf-specific antibody profiles that are associated with protection from malaria using a protein microarray representing 2000 Pf proteins (approximately 40% of the Pf proteome).
Exploratory objectives for this study are to compare the magnitude and quality of the Pf-specific CD4+ T cell response in malaria-protected and -susceptible individuals and determine how this response varies with age and among individuals before, during, and after malaria season, as well as compare various immune parameters in Pf-infected and uninfected individuals at the end of the dry season to investigate host immune factors associated with chronic asymptomatic Pf infection.
Studientyp
Beobachtungs
Einschreibung (Tatsächlich)
1188
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
-
Bamako, Mali
- University of Bamako, Faculty of Medicine, Pharmacy and Odontostomatology
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
3 Monate bis 40 Jahre (Kind, Erwachsene)
Akzeptiert gesunde Freiwillige
Ja
Studienberechtigte Geschlechter
Alle
Probenahmeverfahren
Wahrscheinlichkeitsstichprobe
Studienpopulation
All study subjects will be selected from the village of Kalifabougou, Mali.
Male and female volunteers 3 months to 40 years of age will be included.
This age range captures the period over which immunity to malaria is acquired in areas of intense Pf transmission like Mali.
There is no exclusion based on race, ethnicity, or gender.@@@
Beschreibung
- INCLUSION CRITERIA:
Individuals 3 months to 40 years of age are eligible to enter the study if they agree to:
- Live in Kalifabougou for the duration of the study (12 months).
- Have blood specimens stored for future studies.
EXCLUSION CRITERIA:
The following eligibility criteria are exclusionary:
- Anemia (hemoglobin less than 7 g/dL).
- Current use of antimalarials, corticosteroids, or other immuno-suppressants.
- Underlying heart disease, bleeding disorder, or other conditions that, in the judgment of the clinical investigators, could increase the risk to the study subjects.
- Fever greater than or equal to 37.5 degrees Celsius or evidence of an acute infection.
- Currently pregnant or planning to become pregnant during the study period.
(Asymptomatic Pf infection at enrollment is not exclusionary).
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
---|
observational cohort
This observational-cohort study of individuals (3 months and 40 years of age) will be conducted in the rural village of Kalifabougou, Mali, where Pf transmission is intense and seasonal
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Pf expression profiles
Zeitfenster: Triannual cross-sectional surveys and convalescence visits
|
Identify genome-wide progression profiles induced by Plasmonium falciparum infection that are assocaited with malaria immunity
|
Triannual cross-sectional surveys and convalescence visits
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
serum cytokine profiles
Zeitfenster: Triannual cross-sectional surveys and convalescence visits
|
Examine the relationship between age (surrogate for cumulative Pf exposure) and the gene-expression and serum cytokine profilesinduced by Pf infection.
|
Triannual cross-sectional surveys and convalescence visits
|
Pf-specific antibody profiles
Zeitfenster: Triannual cross-sectional surveys and convalescence visits
|
Identify Pf-specific antibody profiles that are associated with malaria immunity by using a protein microarray representing 2000 Pf proteins (approx.
40% of the Pf proteome), and determine how these profiles change with age.
The objective is to validate and extend findings from a preliminary study performed in the nearby village of Kambila, Mali, where a protein microarray containing approx.
23% of the Pf proteome was used to profile Pf-specific antibody responses in children and adults before and after the 6-month malaria season
|
Triannual cross-sectional surveys and convalescence visits
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Ermittler
- Hauptermittler: Peter D Crompton, M.D., National Institute of Allergy and Infectious Diseases (NIAID)
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Allgemeine Veröffentlichungen
- Tran TM, Aghili A, Li S, Ongoiba A, Kayentao K, Doumbo S, Traore B, Crompton PD. A nested real-time PCR assay for the quantification of Plasmodium falciparum DNA extracted from dried blood spots. Malar J. 2014 Oct 4;13:393. doi: 10.1186/1475-2875-13-393.
- Tran TM, Ongoiba A, Coursen J, Crosnier C, Diouf A, Huang CY, Li S, Doumbo S, Doumtabe D, Kone Y, Bathily A, Dia S, Niangaly M, Dara C, Sangala J, Miller LH, Doumbo OK, Kayentao K, Long CA, Miura K, Wright GJ, Traore B, Crompton PD. Naturally acquired antibodies specific for Plasmodium falciparum reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from malaria. J Infect Dis. 2014 Mar 1;209(5):789-98. doi: 10.1093/infdis/jit553. Epub 2013 Oct 16.
- Doumbo S, Tran TM, Sangala J, Li S, Doumtabe D, Kone Y, Traore A, Bathily A, Sogoba N, Coulibaly ME, Huang CY, Ongoiba A, Kayentao K, Diallo M, Dramane Z, Nutman TB, Crompton PD, Doumbo O, Traore B. Co-infection of long-term carriers of Plasmodium falciparum with Schistosoma haematobium enhances protection from febrile malaria: a prospective cohort study in Mali. PLoS Negl Trop Dis. 2014 Sep 11;8(9):e3154. doi: 10.1371/journal.pntd.0003154. eCollection 2014 Sep.
- Molina-Cruz A, Raytselis N, Withers R, Dwivedi A, Crompton PD, Traore B, Carpi G, Silva JC, Barillas-Mury C. A genotyping assay to determine geographic origin and transmission potential of Plasmodium falciparum malaria cases. Commun Biol. 2021 Sep 30;4(1):1145. doi: 10.1038/s42003-021-02667-0.
- Guha R, Mathioudaki A, Doumbo S, Doumtabe D, Skinner J, Arora G, Siddiqui S, Li S, Kayentao K, Ongoiba A, Zaugg J, Traore B, Crompton PD. Plasmodium falciparum malaria drives epigenetic reprogramming of human monocytes toward a regulatory phenotype. PLoS Pathog. 2021 Apr 6;17(4):e1009430. doi: 10.1371/journal.ppat.1009430. eCollection 2021 Apr.
- Obeng-Adjei N, Larremore DB, Turner L, Ongoiba A, Li S, Doumbo S, Yazew TB, Kayentao K, Miller LH, Traore B, Pierce SK, Buckee CO, Lavstsen T, Crompton PD, Tran TM. Longitudinal analysis of naturally acquired PfEMP1 CIDR domain variant antibodies identifies associations with malaria protection. JCI Insight. 2020 Jun 18;5(12):e137262. doi: 10.1172/jci.insight.137262.
- Liu EW, Skinner J, Tran TM, Kumar K, Narum DL, Jain A, Ongoiba A, Traore B, Felgner PL, Crompton PD. Protein-Specific Features Associated with Variability in Human Antibody Responses to Plasmodium falciparum Malaria Antigens. Am J Trop Med Hyg. 2018 Jan;98(1):57-66. doi: 10.4269/ajtmh.17-0437. Erratum In: Am J Trop Med Hyg. 2018 Feb;98(2):636.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
1. Mai 2011
Primärer Abschluss (Tatsächlich)
28. März 2022
Studienabschluss (Tatsächlich)
29. März 2022
Studienanmeldedaten
Zuerst eingereicht
23. März 2011
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
23. März 2011
Zuerst gepostet (Schätzen)
24. März 2011
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
31. März 2022
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
29. März 2022
Zuletzt verifiziert
1. März 2022
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 999911126
- 11-I-N126
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst und andere MitarbeiterRekrutierungPlasmodium falciparum Malaria | Plasmodium Vivax-MalariaDemokratische Volksrepublik Laos
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanAbgeschlossenVivax-Malaria | Unkomplizierte Falciparum-MalariaAfghanistan
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaAbgeschlossenPlasmodium falciparum Malaria | Plasmodium Vivax-MalariaPeru
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... und andere MitarbeiterAbgeschlossenVerringerung des Risikos von P. vivax nach Falciparum-Infektionen in co-endemischen Gebieten (PRIMA)Malaria | Vivax-Malaria | Falciparum-MalariaÄthiopien, Bangladesch, Indonesien
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...AbgeschlossenPlasmodium falciparum Malaria | Plasmodium Vivax-MalariaIndonesien
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...AbgeschlossenVivax-Malaria | Falciparum-MalariaIndonesien
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... und andere MitarbeiterAbgeschlossenMalaria | Vivax-Malaria | Falciparum-MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...AbgeschlossenVivax-Malaria | Falciparum-MalariaIndonesien
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationAbgeschlossenMalaria | Vivax-Malaria | Falciparum-Malaria | Malaria-Rückfall
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...AbgeschlossenPlasmodium falciparum Malaria | Unkomplizierte Malaria | Malaria-FieberNigeria